Supplementary Figure 2 from Preclinical Evaluation of STI-8811, a Novel Antibody–Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma

2026 Open access

Read full text Summarise with VIRAT
Authors: Aaron D. Springer, Rengang Wang, Jiawei Wang, Qinyi Du, Willie Pi, Austin Q. Nguyen, Xiaoqing Li, Alisher B. Khasanov, Tong Zhu, Zheng Yan, Yufeng Hong, Heyue Zhou
+5 more Yanliang Zhang, Lisa Kerwin, Lingna Li, Henry Ji, Hong Zhang
DOI: 10.1158/2767-9764.31762295
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Figure S2. Long-term tumor suppression study of repeat dosing of STI-8811 in NCI-H929 s.c. xenograft model. SCID-Beige (n = 7) mice were treated i.v. with 4 doses of indicated molecules at biweekly regimen. Data represent mean ± SD

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Monoclonal and Polyclonal Antibodies Research Protein Degradation and Inhibitors

Publication details

Publication date
16 March 2026
Language
EN